[Combined chemo- and radiotherapy in small cell bronchogenic carcinoma].
During a period of 3 years 25 patients with small cell bronchogenic carcinoma were treated with combination chemotherapy and radiotherapy. The regimen was composed of adriamycin, cyclophosphamide and vincristine (ACO). After the first three cycles of combination chemotherapy-radiotherapy treatment was given to the primary tumor, the regional lymph nodes, the mediastinum and clinically involved cervical nodes. All patients showed a complete or partial regression of tumor. The median duration of response of patients with limited disease was 12 months, for those with extended or disseminated disease 8,6 months. Median survival from start of therapy was 14 months for those with limited disease at presentation and 10,9 months for those presenting with disseminated disease. The data were compared with those of other studies and discussed.
D000328:Adult; D000368:Aged; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide
Kombinierte Chemo- und Radiotherapie bei kleinzelligen Bronchuskarzinomen.